General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-13 | 2024-09 | -1.13 | N/A | N/A | N/A |
2024-08-06 | 2024-06 | -1.13 | -1.11 | 0.02 | 1.77% |
2024-05-07 | 2024-03 | -1.45 | -1.21 | 0.24 | 16.55% |
2024-05-07 | 2024-03 | -1.45 | N/A | N/A | N/A |
2024-02-27 | 2023-12 | -1.15 | 1.73 | 2.88 | 250.43% |
2024-02-27 | 2023-12 | -1.15 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-16 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-12 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-28 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-08 | Barclays | Upgrade | Equal-Weight | Equal-Weight |
2023-08-08 | Credit Suisse | Upgrade | Neutral | Neutral |
2023-08-08 | Citigroup | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2020-02-09 | ARCH VENTURE PARTNERS | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
2024-03-31 | BELLON CHRISTINE | Officer | 104.59K | Sale |
2020-02-09 | BUROW KRISTINA M | Director | 0.00 | Conversion of Exercise of derivative security |
2024-04-25 | BURRELL TERRY-ANN | Chief Financial Officer | 82.64K | Stock Award(Grant) |
2024-03-31 | CIARAMELLA GIUSEPPE | President | 169.62K | Sale |
2021-07-05 | COOPER GRAHAM K | Director | 0.00 | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | ARK Investment Management, LLC | 8.78M | 211.25M | 11.09% |
2023-06-29 | FMR, LLC | 7.14M | 227.91M | 9.01% |
2023-06-29 | Vanguard Group Inc | 7.01M | 223.83M | 8.85% |
2023-06-29 | Blackrock Inc. | 6.35M | 202.78M | 8.02% |
2023-06-29 | Temasek Holdings (Private) Limited | 4.32M | 137.87M | 5.45% |
2023-06-29 | State Street Corporation | 3.59M | 114.53M | 4.53% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-09-29 | ARK ETF Tr-ARK Innovation ETF | 6.08M | 146.27M | 7.68% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.38M | 75.87M | 3.00% |
2023-09-29 | ARK ETF Tr-ARK Genomic Revolution ETF | 2.25M | 54.05M | 2.84% |
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.17M | 50.37M | 2.74% |
2023-06-29 | Vanguard Small-Cap Index Fund | 1.87M | 59.69M | 2.36% |
2023-08-30 | iShares Russell 2000 ETF | 1.56M | 36.25M | 1.97% |
Dividend | Date |
---|---|
0.225 | 2014-02-04 |
0.225 | 2013-11-04 |
0.225 | 2013-08-12 |
0.225 | 2013-05-06 |
0.225 | 2013-02-04 |
0.21 | 2012-11-05 |
New CRISPR/Cas9 patent issued to Carribou Bio $CRBU
$CRBU
Take a look at Caribou Biosciences.
Leader in CRISPR Gene editing. Cure to all diseases.
Founded by Nobel winner Jennifer Doudna and CEO Rachel Haurwitz.
Market cap 1.3 Billion.
They have 14,453,932 shares of Intellia (NTLA). Worth $2.5 Billion alone. Check out filings:
https://www.sec.gov/edgar/browse/?CIK=1619856&owner=exclude
They have about $500 Million in cash from recent IPO.
Listen to The Code Breaker by Walter Isaacson on Audible. https://www.audible.com/pd?asin=179711705X&source_code=ASSORAP0511160006
Check out patents:
Working on cure for cancer.
This has potential for x 1000
Do your own due diligence.
Good luck